HIV Fat Redistribution and the Evaluation of Brown Fat (NCT01098045) | Clinical Trial Compass
CompletedNot Applicable
HIV Fat Redistribution and the Evaluation of Brown Fat
United States27 participantsStarted 2010-03
Plain-language summary
The specific aims of this study are to determine whether HIV-infected patients with significant fat redistribution and ectopic fat accumulation have increased brown adipose tissue using 18F-FDG Positron Emission Tomography techniques.
Recent studies suggest down regulation of Dicer, a major component of miRNA has an important role in the differentiation and function of brown and white adipose tissue and may contribute to lipodystrophy. Therefore we will expand on recent research in this area by recruiting HIV-infected men with lipodystrophy. We will perform subcutaneous fat biopsies of the dorsocervical and abdominal fat in a subset of HIV-infected and non-HIV-infected men in order to explore further the question of down regulation of Dicer and its implication on metabolic abnormalities in this population.
Who can participate
Age range20 Years – 60 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Evidence of HIV infection
✓. Age ≥ 20 and ≤ 60 years of age
✓. BMI measurement between 25-29.9 kg/m2
✓. HIV positive, on a stable HAART treatment regimen (including an NRTI) for \> 12 months
✓. Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck.
Exclusion criteria
✕. Hemoglobin \< 10.0 g/dL
✕. Diabetes or on medications for diabetes
✕. Abnormal thyroid function
✕. Therapy with medications such as beta blockers, alpha-blockers, sympatholytic drugs
✕. Chronic adrenergic drug use (\>3 months) and benzodiazepine use.